Analystreport

Esperion Therapeutics (NASDAQ:ESPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.

Esperion Therapeutics, Inc.  (ESPR) 
Last esperion therapeutics, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.esperion.com